“The charges filed today in the United States In the Eastern District Court of Pennsylvania is an indication of my office`s ongoing efforts to investigate and indict companies and executives who set generic drug prices,” said U.S. Attorney McSwain. We and our partners in the antitrust department and other federal law enforcement continue to focus heavily on price agreements and the illegal awarding of generic drug contracts. These charges and the resulting agreement on deferred prosecutions, subject to the approval of the Tribunal, are another significant achievement in this area. As part of an agreement with the DOJ for a deferred prosecution, the DOJ will present information regarding conduct that took place between 2013 and 2015. If the company complies with the terms of the agreement, including the payment of $205.7 million, the DOJ will refuse the information at the end of a three-year period. The company also entered into a framework agreement with the DOJ Civil Division, subject to the final agreement and approval of the AUTHORITY, in which the company agreed to pay $213.3 million to resolve all claims related to public health programs. .